|
|
|
|
Modulatory Effect of Raloxifene and Estrogen on the Metabolic Action of Growth Hormone in Hypopituitary Women
Birzniece V et al.The modulatory effects of E2 and R at therapeutic doses on GH action are different. Modulatory Effect of Raloxifene and Estrogen on the Metabolic Action of Growth Hormone in Hypopituitary Women.
|
|
|
Letter: Available cancer drugs are not being used
I found this article by Gina Kolata in the New York Times and hope it will be of interest.Many Americans do not think twice taking medicines to prevent heart disease and stroke. But cancer is different. The few medicines proved to deter cancer are wildly...
|
|
|
Apoptosis Therapy: New apoptosis therapy study findings have been reported by scientists at Fox Chase Cancer Center
Today's Medical & Research News Apoptosis Therapy New apoptosis therapy study findings have been reported by scientists at Fox Chase Cancer Center February 27th, 2010 Printer-Friendly Version City:Philadelphia State:PA Country:United States Apoptosis...
|
|
|
Pfizer osteoporosis drug gets lukewarm review
Get IOL on your mobile at m.iol.co.za Pfizer's experimental osteoporosis drug lasofoxifene, which is awaiting US regulatory approval, works about as well as currently approved drugs, but not much better, according to a commentary published on Wednesday in the...
|
|
|
Pfizer osteoporosis drug gets lukewarm review
* Experimental drug about same as Lilly's Evista -expert * Findings test FDA appetite for 'me-too' drugs In the current climate of comparative effectiveness research -- where drug companies are being asked to prove their drugs work better than others' products ...
|
|
|
Pfizer osteoporosis drug gets lukewarm review
* Experimental drug about same as Lilly's Evista -expert * Lasofoxifene data left one expert 'underwhelmed' * Findings test FDA appetite for 'me-too' drugs CHICAGO, Feb 24 (Reuters) - Pfizer's experimental osteoporosis drug lasofoxifene, which is awaiting U.S....
|
|
|
Teva moves closer to generic Evista sales in Europe: Sales of the branded drug are $1 billion worldwide, inclu
Generic pharmaceuticals company Teva Pharmaceutical Industries Ltd.( NASDAQ:TEVA; TASE: TEVA) is a step closer to marketing a generic version of osteoporosis drug Evista (Raloxifene) in Europe. In September, a US court ruled against Teva...
|
|
|
Teva moves closer to generic Evista sales in Europe: Sales of the branded drug are $1 billion worldwide, inclu
21Generic pharmaceuticals company Teva Pharmaceutical Industries Ltd.(Nasdaq: TEVA; TASE: TEVA) is a step closer to marketing a generic version of osteoporosis drug Evista (Raloxifene) in Europe. In September, a US court ruled against Teva...
|
|
|
Teva moves closer to generic Evista sales in Europe: Sales of the branded drug are $1 billion worldwide, including about $350 mi
(Globes - McClatchy-Tribune Information Services via COMTEX) -- Generic pharmaceuticals company Teva Pharmaceutical Industries Ltd.(Nasdaq: TEVA; TASE: TEVA | Quote | Chart | News | PowerRating) is a step closer to marketing a generic version of osteoporosis...
|
|
|
Sanofis Humenza poised to be Europes fifth swine flu vaccine
Sanofi Pasteurs Humenza is set to become the fifth swine flu vaccine in Europe after gaining the support of a key regulatory committee.The Committee for Medicinal Products for Human Use (CHMP) recommended the vaccine for European approval under its emergency...
|
|
|
Teva moves closer to generic Evista sales in Europe: Sales of the branded drug are $1 billion worldwide, inclu
21--Generic pharmaceuticals company Teva Pharmaceutical Industries Ltd.(Nasdaq: TEVA; TASE: TEVA) is a step closer to marketing a generic version of osteoporosis drug Evista (Raloxifene) in Europe. In September, a US court ruled against Teva...
|
|
|
Teva moves closer to generic Evista sales in Europe: Sales of the branded drug are $1 billion worldwide, inclu
21--Generic pharmaceuticals company Teva Pharmaceutical Industries Ltd.(Nasdaq: TEVA; TASE: TEVA) is a step closer to marketing a generic version of osteoporosis drug Evista (Raloxifene) in Europe. In September, a US court ruled against Teva...
|
|
|
Teva moves closer to generic Evista sales in Europe
Sales of the branded drug are $1 billion worldwide, including about $350 million outside the US.Shiri Habib-Valdhorn21 Feb 10 18:11 Generic pharmaceuticals company Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) is a step closer to marketing...
|
|
|
Summary of opinion (initial authorisation) Raloxifene Teva raloxifene hydrochloride
the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Raloxifene Teva 60 mg Film-coated Tablets intended for treatment and prevention of...
|
|
|
EU Panel Adopts Positive Opinion On Votrient From Glaxo
LONDON -(Dow Jones)- The Agency's Committee for Medicinal Products for Human Use, or CHMP, said Friday it has adopted a positive opinion, recommending the granting of a conditional marketing authorization, for Votrient (pazopanib), from Glaxo Group Ltd (GSK),...
|
|
|
EU Panel Adopts Positive Opinion On Votrient From Glaxo
LONDON -(Dow Jones)- The Agency's Committee for Medicinal Products for Human Use, or CHMP, said Friday it has adopted a positive opinion, recommending the granting of a conditional marketing authorization, for Votrient (pazopanib), from Glaxo Group Ltd (GSK),...
|
|
|
EU Panel Adopts Positive Opinion On Votrient From Glaxo
LONDON -(Dow Jones)- The Agency's Committee for Medicinal Products for Human Use, or CHMP, said Friday it has adopted a positive opinion, recommending the granting of a conditional marketing authorization, for Votrient (pazopanib), from Glaxo Group Ltd (GSK),...
|
|
|
EU Panel Adopts Positive Opinion On Votrient From Glaxo
LONDON -(Dow Jones)- The Agency's Committee for Medicinal Products for Human Use, or CHMP, said Friday it has adopted a positive opinion, recommending the granting of a conditional marketing authorization, for Votrient (pazopanib), from Glaxo Group Ltd (GSK),...
|
|
|
TopAbstracts in Vascular Disorders 02/18/2010
TopAbstracts in Vascular Disorders are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 14 days.Over 2000 peer-reviewed journals are...
|
